OCON Therapeutics Overview
OCON Therapeutics innovates, develops, manufactures, and commercializes women's health products based on its proprietary and patented intrauterine ball (IUB) platform. Made from the super-elastic alloy nitinol, the IUB is an ideal carrier of multiple drugs to the uterus for treating a variety of conditions. In addition to its flagship product, the IUB Ballerine, OCON Therapeutics is developing a pipeline of products utilizing the IUB frame for indications including abnormal uterine bleeding, heavy menstrual bleeding, myomas and fibroids, and infertility.
Cumulative Funding Raised Over Time ($)
$4.5MDec 2020
$7.5MJan 2014
$10.5MJan 2016
$12.5MJun 2020
$22.5MJun 2024
$23.0MMar 2011
$24.5MMay 2013
$24.5MOct 2017
Latest News
growth-positive
OCON Therapeutics raises $10 million for innovative IUD and women’s health solutions | CTech
Israeli femtech firm OCON Therapeutics has raised $10 million in a funding round led by RH Capital, with participation from Features Capital, Astia Angels, Exerte Partners, the Israeli Innovation Authority, and angel investors. The company, which has raised a total of $40 million to date, will use the new funds to expand its treatment solutions for uterine health issues. OCON is known for its patented IUD, the Ballerine, which has been used by over 150,000 women. The company aims to address prevalent uterine pathologies with targeted and lower-dose treatments.
InvestmentExpand
growth-positive
OCON Therapeutics Raises $10M in Funding
Ocon Therapeutics, a health company based in Modiin, Israel, has raised $10M in funding. The round was led by RH Capital, with participation from Features Capital, Astia Angels, and Exerte Partners. The company, which specializes in drug delivery systems, intends to use the funds to enhance its ability to provide solutions for treating prevalent uterine pathologies. Ocon Therapeutics is dedicated to developing, manufacturing, and commercializing 3D drug delivery systems based on its patented IUB® (Intra-Uterine Ball) platform.
Investment
growth-positive
OCON Therapeutics improving women's quality of life with innovative IUD design and targeted health solutions | CTech
OCON Therapeutics is pioneering painless and effective IUDs for women and addressing womens health issues like endometriosis and uterine fibroids. The companys non-hormonal IUB, called Ballerine, offers a smaller and more comfortable alternative to traditional IUDs. OCON has also developed IUBs that target specific issues such as endometriosis and heavy menstrual bleeding. The CEO of OCON Therapeutics, Keren Leshem, emphasizes the need for better products that are safe and effective for womens anatomy. The market for womens health issues is lucrative and relatively untapped. OCON Therapeutics has raised $30 million in funding and is in the process of raising their Series B round.
CustomersInvestment
growth-positive
Significant breakthrough: The FEMTECH company OCON Healthcare of the Merchavia Investments Group has signed an exclusive agreement with BioGenuine to market its products in China and Southeast Asian countries
OCON Healthcare, an Israeli FEMTECH company, has signed a binding agreement with BioGenuine, a Chinese pharma company, for the exclusive marketing of OCONs products in China and Southeast Asia. The companies will also collaborate on the development and commercialization of new products in the field of womens health. OCON will receive an immediate payment of $1.3 million and additional milestone payments. OCONs first product, the Ballerine® (IUB™ Ballerine®), is a spherical intrauterine device for pregnancy prevention. OCONs second product, SEAD IUB, is in a Phase 2b clinical trial for non-invasive treatment of Heavy Menstrual Bleeding. OCON is also developing a new product, IUB PRIMA, for sustained drug release in the uterus.
Partners
growth-positive
האם התקן תוך רחמי בצורת כדור ישנה את האופן שבו מטפלים בנשים?
OCON, an Israeli start-up that developed an intrauterine device for contraception, was on the brink of closure two and a half years ago. However, the company was saved by a surprise phone call from an investor from Pontifax, the company with the largest shares in OCON. The company has since developed a device called Ballerine, which has been installed in 120,000 women, 10,000 of whom are in Israel, with the rest in Europe and South Africa. OCON is now looking to expand into the US and has begun processes to obtain FDA approval.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $24.5M |
| Last funding | $10M |
| Stage | A |
| Rounds | 8 |
| Investors | 12 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | oconmed.com |
| Careers | Careers page |
Locations
HaMiktsoot Blvd 14, Modi'in-Maccabim-Re'ut, Israel
Herostrasse 12, 8048 Zrich, Switzerland
Photos & Videos
3 item(s)
OCON Therapeutics Business
Business models
B2B, B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCommerce & RetailDistribution ChannelsDistributorConsumersDemographics & FamilyWomenCore Technology
Materials & SubstancesImplantsTags (11)
femtechpreventionmedical-productsmedical-devicespregnancygynecologywomen-healthnon-invasivewomenpatientstreatmentsGeographic Markets
AustraliaAfricaAsiaEuropeAmericasSouth AmericaChinaOCON Therapeutics Financials
$24.5M
Total funding
Undisclosed
Capital raised
$10M
Last funding
A
Funding stage
8
Total rounds
12
Investors
Cumulative Funding Raised Over Time ($)
$4.5MDec 2020
$7.5MJan 2014
$10.5MJan 2016
$12.5MJun 2020
$22.5MJun 2024
$23.0MMar 2011
$24.5MMay 2013
$24.5MOct 2017
Private Equity Funding
A Round
Jun 2024
$10M
Rhia Ventures (Lead)
,
Exerte Partners, Features Capital, Astia Angels
A Round
Dec 2020
$4.5M
Rhia Ventures (Lead), Pontifax (Lead)
,
Astia Angels, Merchavia Holdings, Docor International Management
Undisclosed Round
Jun 2020
$2M
Docor International Management, Pontifax
Undisclosed Round
Oct 2017
Undisclosed
Chemo Group
Undisclosed Round
Jan 2016
$3M
Abu Dhabi Education Council, EBR
Undisclosed Round
Jan 2014
$3M
RMI Partners, Docor International Management, Pontifax
Undisclosed Round
May 2013
$1.5M
Aliment Capital, Docor International Management
Seed
Mar 2011
$500K
Docor International Management
OCON Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$4.5MDec 2020
$7.5MJan 2014
$10.5MJan 2016
$12.5MJun 2020
$22.5MJun 2024
$23.0MMar 2011
$24.5MMay 2013
$24.5MOct 2017
All Events
A Round
Jun 2024
$10M
Rhia Ventures (Lead)
,
Exerte Partners, Features Capital, Astia Angels
A Round
Dec 2020
$4.5M
Rhia Ventures (Lead), Pontifax (Lead)
,
Astia Angels, Merchavia Holdings, Docor International Management
Undisclosed Round
Jun 2020
$2M
Docor International Management, Pontifax
Undisclosed Round
Oct 2017
Undisclosed
Chemo Group
Undisclosed Round
Jan 2016
$3M
Abu Dhabi Education Council, EBR
Undisclosed Round
Jan 2014
$3M
RMI Partners, Docor International Management, Pontifax
Undisclosed Round
May 2013
$1.5M
Aliment Capital, Docor International Management
Seed
Mar 2011
$500K
Docor International Management
OCON Therapeutics News
21 articles
growth-positive
OCON Therapeutics raises $10 million for innovative IUD and women’s health solutions | CTech
Israeli femtech firm OCON Therapeutics has raised $10 million in a funding round led by RH Capital, with participation from Features Capital, Astia Angels, Exerte Partners, the Israeli Innovation Authority, and angel investors. The company, which has raised a total of $40 million to date, will use the new funds to expand its treatment solutions for uterine health issues. OCON is known for its patented IUD, the Ballerine, which has been used by over 150,000 women. The company aims to address prevalent uterine pathologies with targeted and lower-dose treatments.
InvestmentExpand
growth-positive
OCON Therapeutics Raises $10M in Funding
Ocon Therapeutics, a health company based in Modiin, Israel, has raised $10M in funding. The round was led by RH Capital, with participation from Features Capital, Astia Angels, and Exerte Partners. The company, which specializes in drug delivery systems, intends to use the funds to enhance its ability to provide solutions for treating prevalent uterine pathologies. Ocon Therapeutics is dedicated to developing, manufacturing, and commercializing 3D drug delivery systems based on its patented IUB® (Intra-Uterine Ball) platform.
Investment
growth-positive
OCON Therapeutics improving women's quality of life with innovative IUD design and targeted health solutions | CTech
OCON Therapeutics is pioneering painless and effective IUDs for women and addressing womens health issues like endometriosis and uterine fibroids. The companys non-hormonal IUB, called Ballerine, offers a smaller and more comfortable alternative to traditional IUDs. OCON has also developed IUBs that target specific issues such as endometriosis and heavy menstrual bleeding. The CEO of OCON Therapeutics, Keren Leshem, emphasizes the need for better products that are safe and effective for womens anatomy. The market for womens health issues is lucrative and relatively untapped. OCON Therapeutics has raised $30 million in funding and is in the process of raising their Series B round.
CustomersInvestment
growth-positive
Significant breakthrough: The FEMTECH company OCON Healthcare of the Merchavia Investments Group has signed an exclusive agreement with BioGenuine to market its products in China and Southeast Asian countries
OCON Healthcare, an Israeli FEMTECH company, has signed a binding agreement with BioGenuine, a Chinese pharma company, for the exclusive marketing of OCONs products in China and Southeast Asia. The companies will also collaborate on the development and commercialization of new products in the field of womens health. OCON will receive an immediate payment of $1.3 million and additional milestone payments. OCONs first product, the Ballerine® (IUB™ Ballerine®), is a spherical intrauterine device for pregnancy prevention. OCONs second product, SEAD IUB, is in a Phase 2b clinical trial for non-invasive treatment of Heavy Menstrual Bleeding. OCON is also developing a new product, IUB PRIMA, for sustained drug release in the uterus.
Partners
growth-positive
האם התקן תוך רחמי בצורת כדור ישנה את האופן שבו מטפלים בנשים?
OCON, an Israeli start-up that developed an intrauterine device for contraception, was on the brink of closure two and a half years ago. However, the company was saved by a surprise phone call from an investor from Pontifax, the company with the largest shares in OCON. The company has since developed a device called Ballerine, which has been installed in 120,000 women, 10,000 of whom are in Israel, with the rest in Europe and South Africa. OCON is now looking to expand into the US and has begun processes to obtain FDA approval.
InvestmentExpand
growth-positive
Her body - not her choice: Technology's role in the face of government conservatism CTech
Keren Leshem, CEO of OCON Healthcare, discusses the growing importance of femtech and womens health technologies. Despite the industry still being relatively young, there is a growing need for differentiated care delivery for women due to their diverse physiology and societal roles. Israel is becoming a leader in this space, with about 200 Israeli companies in various sub-sectors of womens health and femtech. However, femtech companies only received 3% of health technology funding in 2020, with less than 2% of all venture capital invested in women-led companies. Leshem calls for more investment and innovation in this sector.
InvestmentExpand
growth-positive
OCON Healthcare Awarded as Technology Pioneer by the World Economic Forum
OCON Healthcare, a womens health company, has been selected as one of the World Economic Forums Technology Pioneers of 2022. The company has developed a three-dimensional intrauterine drug-delivery platform technology that addresses various womens health issues. OCON Healthcares selection as a Technology Pioneer will allow its CEO, Keren Leshem, to participate in World Economic Forum activities and contribute to initiatives over the next two years. The company is honored to be recognized for its contribution to shaping the future of womens health and looks forward to working with global leaders to advance female health and leadership. The Technology Pioneers community consists of early to growth-stage companies involved in new technologies and innovations.
Customers
growth-positive
OCON Healthcare Develops New Women's Health Devices
Israeli FemTech startup OCON Healthcare manufactures innovative 3D intrauterine devices (IUD) for women. The company aims to provide women with more freedom and control over their bodies. OCONs CEO, Keren Leshem, believes that the traditional IUD market is worth billions of dollars and sees great potential in the companys products. OCON is currently developing a hormonal version of its IUD for contraception and to treat menstrual disorders. The company is in Phase 2 Clinical Trials for its intrauterine drug delivery technology. Despite facing adversity during the COVID-19 pandemic, OCON remains optimistic about its future and aims to become a womens health hub. The company is predominantly run by women and emphasizes the importance of diversity in developing products for womens health. OCONs investors hope for a profitable exit through an IPO or acquisition.
InvestmentExpand
growth-positive
Frost & Sullivan Awards OCON Healthcare with the 2021 Global Enabling Technology Leadership Award
OCON Healthcare has been recognized by Frost & Sullivan for creating the worlds first 3D spherical copper IUD, the Intra Uterine Ball (IUB) Ballerine. The IUD is made from nitinol and is hormone-free, flexible, and effective for up to five years. It has received four global regulatory approvals and has a high market acceptance potential. OCON Healthcares technology is available in 30 countries. The IUB Ballerine offers improved safety and comfort compared to conventional T-shaped IUDs. It is suitable for young women from 15 years of age. The company is also developing solutions for fibroids, endometriosis, cancers, and other hormonal therapies.
Customers
growth-positive
אוקון הלת' קר: תוצאות ניסוי טובות בטיפול בדימום חריג מהרחם
Medical device company אוקון הלת קר announced positive results and completion of patient recruitment for a Phase IIa trial for the treatment of abnormal uterine bleeding. The company has developed round intrauterine devices that are coated with a chemical compound that causes the shedding of the uterine lining in women suffering from bleeding. The treatment is expected to last for half an hour. The companys new device aims to provide a simple and innovative solution for the treatment of abnormal uterine bleeding without the need for invasive procedures or hysterectomy. The market for procedures related to abnormal uterine bleeding is estimated to reach $1.3 billion by 2024.
Investment
growth-positive
Dr. Robert Auerbach joins femtech startup OCON Healthcare's Board of Directors - retired President of CooperSurgical
OCON Healthcare, a femtech company, has appointed Dr. Robert Auerbach to its Board of Directors. Dr. Auerbach has extensive experience in the womens healthcare industry and will provide guidance and leadership to the growing company. OCONs flagship product, the IUBTM Ballerine®, is a non-hormonal smart contraceptive ball with approvals and distribution agreements totaling over $35 million. The company is also developing the IUBTM SEADTM, a non-hormonal treatment for abnormal uterine bleeding. OCON is commercially active in 30 countries and has existing sales of over $7 million.
Management Changes
growth-positive
OCON Healthcare Announces Positive Long-Term efficacy and safety data on over 100K users of its Smart IUB Ballerine Hormone-Free Contraceptive
OCON Healthcare announced positive worldwide data on the efficacy and safety of its IUB Ballerine, a smart 3D hormone-free intrauterine contraceptive. The real-world data collected from over 100,000 women showed significant safety benefits compared to traditional T-shaped IUDs. The IUB Ballerine had a lower risk of ectopic pregnancies and perforation, as well as a lower expulsion rate. OCON Healthcare also mentioned its other pipeline products in development, including the IUB SEAD for Abnormal Uterine Bleeding. The company recently completed an investment round led by Rhia Ventures to bring its products to the U.S. market and expand clinical trials. Additional funding is expected in 2021.
CustomersPartnersInvestment
growth-positive
"COVID is a Great Teacher," Says Femtech Startup OCON Healthcare's CEO, Keren Leshem
OCON Healthcare, an Israeli femtech start-up, has developed the IUB, a revolutionary intrauterine platform for womens health. Their first commercial product, IUB Ballerine, is a hormone-free contraceptive device that has gained approvals and is being used by 100,000 women in 30 countries. Their second product, SEAD, is undergoing clinical trials for non-invasive treatment of abnormal uterine bleeding. The COVID-19 pandemic has affected their business, with slower sales in some regions, but they have adapted by reducing costs and expanding online business development. OCON Healthcare has faced difficult choices but has received new investments and support from their board. They aim to stay competitive by forming alliances with experienced distributors and offering a unique and innovative solution in the market.
Customers
growth-positive
FemTech startup OCON Healthcare completes funding round and appoints Dr. Anula Jayasuriya to Chairwoman
OCON Healthcare has completed a funding round led by Rhia Ventures to bring its IUB Ballerine contraceptive and IUB SEAD point-of-care therapy for Abnormal Uterine Bleeding (AUB) to the US market. The company also appointed Dr. Anula Jayasuriya as Chairwoman. The funding round included new and existing investors such as Rhia Ventures, Pontifax VC, and Astia Angels. OCONs flagship product, the IUB Ballerine, is commercially available in 30 countries. The company expects another funding round in 2021.
InvestmentManagement Changes
growth-positive
Rhia Ventures Invests in OCON Healthcare's Ballerine®, the first ever 3D spherical copper intrauterine contraceptive with a superior safety profile, a breakthrough in women's hormone-free birth control options
Rhia Ventures has invested in OCON Healthcare to assist the US launch of Ballerine®, a 3D spherical copper intrauterine contraceptive. The investment will also support the expansion of Phase II clinical trials for OCONs SEADTM product, which offers therapy for abnormal uterine bleeding. Rhia Ventures focuses on contraceptive innovations and womens reproductive health. The investment aims to provide safer and more cost-effective solutions for women and address the unmet need in the market for new contraceptives. OCON Healthcare is excited about the partnership and the opportunity to continue innovating in womens health.
Investment
growth-positive
Shani Gross-Eliyahu OCON, chief technology officer
Israel-based femtech company OCON has appointed Shani Gross-Eliyahu as chief technology officer. The company also announced the appointment of Dana Raveh-Arbel as vice president of clinical affairs and Avital Gilad as its Israel country manager.
Management Changes
growth-positive
אוקון הלת'קר חתמה על הסכמי הפצה בהיקף 13 מיליון דולר
OCON Healthcare, a company that develops innovative intrauterine devices, has announced that it has signed distribution agreements with two distributors, one in South America and the other in England and Ireland. This brings the number of countries where the product is marketed to 30. The company has so far recorded revenues of $7 million and has signed distribution agreements expected to yield a total of $35 million. The implementation of the recently signed agreements is expected in the fourth quarter of 2020. The company recently raised $2 million from Pontifax and Ducor.
PartnersInvestmentExpand
growth-positive
FemTech co OCON Healthcare wins $13m intrauterine orders
Israeli FemTech company OCON Healthcare has signed distribution agreements with DKT and Consilient Healthcare, allowing their spherical intrauterine platform for contraception to be commercially available in 30 countries. The company has received $13 million in intrauterine orders and has sales exceeding $7 million. The agreements are expected to contribute to the companys growth in the contraceptive market, which is showing strong year-on-year growth.
CustomersPartners
growth-positive
OCON CEO promotes intrauterine innovation
Keren Leshem has been appointed CEO of OCON Healthcare, a womens healthcare startup that develops intrauterine products to prevent pregnancy and treat abnormal uterine bleeding. The company has developed the IUB Ballerine, a 3D ball-shaped intrauterine solution that is safer than traditional 2D T-shaped plastic IUDs. OCON is also developing the SEAD solution for treating abnormal uterine bleeding. The company recently won the Seal of Excellence for research and innovation from the European Commission. Leshem replaces Ariel Weinstein as CEO.
Management Changes
growth-positive
The pioneering contraceptive ball that could replace the coil
Ocon Medicals hormone-free contraceptive ball, called Ballerine, is being hailed as a safe and comfortable alternative to metal coils for British women. The device, shaped like a ball, is said to reduce the risk of complications in the uterus and can remain effective for up to ten years. Clinical trials have shown that the Ballerine significantly reduces bleeding and pain compared to traditional IUDs. Ocon Medical plans to offer the device to private UK clinics in April before NHS distribution.
Customers
growth-positive
Israeli gynecologist builds a better IUD
OCON Medical, an Israeli company, has developed a contraceptive device called Ballerine, which is based on the trademarked IUB (Intra Uterine Ball). The device is designed to provide greater comfort and safety compared to traditional IUDs. Ballerine is spherical, soft, and has no sharp edges, reducing the likelihood of mal-positioning and associated pain and bleeding. The device has been on the market since 2014 and is sold in Israel and 19 countries across Europe and Africa. OCON Medical is pursuing FDA clearance in the United States and plans to conduct a large multi-center study to support the application. The company has received significant interest from international drug companies and is backed by several investors, including Pontifax, RMI, Docor International, E. Burke Ross, Geddes Parsons, and Chemo Group.
CustomersPartners
OCON Therapeutics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 34 |
| Team members | 7 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 17 classification IDs that could be used for matching.
OCON Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514568328 |
| Crunchbase | ocon-medical |
| Phone | +972722150105 |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-07-02T00:00:00.000Z |
| Created | 2014-11-10T00:00:00.000Z |
| Claimed | Yes |